Related Experiment Videos
Digitalis in patients after myocardial infarction
1Feiring Clinic, Feiring, Norway.
Insights
Digitalis offers modest benefits for cardiac patients with sinus rhythm and left ventricular dysfunction. However, its impact on survival after myocardial infarction remains controversial, requiring further research.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Digitalis has a long history in treating cardiac disease, yet its precise clinical impact and effects on survival are debated.
- Controversy persists regarding digitalis's role, particularly in patients post-myocardial infarction.
Purpose of the Study:
- To assess the clinical efficacy of digitalis in patients with sinus rhythm and left ventricular dysfunction.
- To evaluate the controversial impact of digitalis on mortality rates in patients following myocardial infarction.
Main Methods:
- Review of recent studies investigating digitalis in patients with sinus rhythm and left ventricular dysfunction.
- Analysis of existing data on digitalis use and mortality in post-myocardial infarction patients.
Main Results:
- Studies suggest a modest clinical benefit from digitalis in patients with sinus rhythm and left ventricular dysfunction.
- Data on digitalis and post-myocardial infarction mortality remain conflicting, with differing interpretations of increased mortality rates.
Conclusions:
- Digitalis may offer a modest clinical benefit for specific cardiac conditions.
- The effect of digitalis on mortality after myocardial infarction is uncertain and requires a large, randomized trial for definitive answers.
- Current evidence supports digitalis as a first-line therapy for atrial fibrillation with left ventricular dysfunction and as a reserved option for symptomatic heart failure patients unresponsive to other treatments.
Abstract:
For more than two centuries digitalis has been used in the treatment of cardiac disease. Despite this long clinical experience with the drug, controversy still exists as to its clinical effect and impact on survival, especially in patients after myocardial infarction. In the last decade a number of studies have addressed the problem of assessing the clinical effect of digitalis in patients with sinus rhythm and left ventricular dysfunction. An overall conclusion from these studies seems to indicate that a modest clinical beneficial effect can be expected from the drug. Regarding the effect of digitalis on the mortality in patients after a myocardial infarction controversy still prevails. All studies show an increased mortality in patients using digitalis, but opinions differ as to whether this is due solely to baseline imbalances between the populations or that a harmful effect of digitalis itself exists as well. This question cannot be answered with certainty until the results from a large, randomized study are available. In the meantime digitalis can probably be used as a first line therapy in patients with atrial fibrillation and left ventricular dysfunction. In patients with sinus rhythm and heart failure, however, it is probably wise to reserve digitalis to those that are still symptomatic after diuretics, nitrates and ACE inhibitors have been tried.